LORIGERLIMAB
UNII JM802R57SA

Substance Identification & Data

This profile provides standardized clinical and technical data for Lorigerlimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) JM802R57SA.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2416595-46-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

JM802R57SA

CAS Registry Number

2416595-46-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LORIGERLIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C158505

National Cancer Institute reference terminology for clinical and research data.

INN ID

11771

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-188

Identifier assigned by the United States Adopted Names Council.

Substance Type

LORIGERLIMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lorigerlimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LORIGERLIMAB

Common Names & Synonyms

IMMUNOGLOBULIN G4 SCFV-H-CH2-CH3_SCFV, ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD1, PD-1, CD279)) AND ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), CHIMERIC, HOMO SAPIENS AND HUMANIZED MONOCLONAL ANTIBODY, TETRAVALENT, BISPECIFIC; SCFV-H-CH2-CH3, CHIMERIC AND HOMO SAPIENS, ANTI-PDCD1 AND ANTI-CTLA4 (1-499) (SCFV-V-KAPPA-VH (1-237) (V-KAPPA ANTI-PDCD1 MUSMUS/HOMSAP (MUS MUSCULUS IGKV3-2*01 (80.8%)-(IGHD)-IGKJ2*01 (91.7%) L124>V (108)/HOMO SAPIENS IGKV3D-11*02 (77.7%)-(IGHD)-IGKJ4*01 (100%), CDR-IMGT (10.3.9) (27-36.54-56.93-101)) (1-111)-8 MER TRIGLYCYL-SERYL-TETRAGLYCYL LINKER (112-119)-VH ANTI-CTLA4 (HOMO SAPIENS IGHV3-30*01 (93.9%)-(IGHD)-IGHJ4*01 (100%), CDR-IMGT (8.8.11) (145-152.170-177.216-226)) (120-237))-E-COIL LINKER (238-271) (6-MER DIGLYCYL-CYSTEINYL-TRIGLYCYL LINKER (238-243)-28-MER (GLUTAMYL-VALYL-DIALANYL-CYSTEINYL-GLUTAMYL-LYSYL)-TRIS(GLUTAMYL-VALYL-DIALANYL-LEUCYL-GLUTAMYL-LYSYL) E-COIL MOTIF (244-271))-(SCFC HOMO SAPIENS IGHG4*01 H-CH2-CH3, G4V5 H P10, G4V21 CH2 Y15.1, T16, E18 (HINGE 1-12 S10>P (281) (272-283), CH2 M15.1>Y (305), S16>T (307), T18>E (309) (284-393), CH3 (394-498), CHS K2>DEL (499)) (272-499)) (248''-246')-DISULFIDE WITH SCFV-V-KAPPA-VH, HOMO SAPIENS AND HUMANIZED, ANTI-CTLA4 AND ANTI-PDCD1 (1'-269') (V-KAPPA ANTI-CTLA4 (HOMO SAPIENS IGKV3-20*01 (99.0%)-IGKJ1*01 (100%), CDR-IMGT (7.3.9) (27-33.51-53.90-98)) (1'-108')-8 MER TRIGLYCYL-SERYL-TETRAGLYCYL LINKER (109'-116')-VH ANTI-PDCD1 (HOMO SAPIENS IGHV1-46*01 (81.6%)-(IGHD)-IGHJ4*01 (92.9%), CDR-IMGT (8.8.12) (142-149.167-174.213-224)) (117'-235'))-K-COIL LINKER (236'-269') (6-MER DIGLYCYL-CYSTEINYL-TRIGLYCYL LINKER (236'-241')-28-MER (LYSYL-VALYL-DIALANYL-CYSTEINYL-LYSYL-GLUTAMYL)-TRIS(LYSYL-VALYL-DIALANYL-LEUCYL-LYSYL-GLUTAMYL) K-COIL MOTIF (242'-269')); DIMER (279-279'':282-282'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-S CELL LINE, GLYCOFORM ALFA

IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS CLONE MG13.78 .KAPPA.-CHAIN V-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGGSGGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN CLONE 4B6 HEAVY CHAIN V-D-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGCGGG) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC E-COIL) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (10-PROLINE,34-TYROSINE,36-THREONINE,38-GLUTAMIC ACID,DE-229-LYSINE) (HUMAN .GAMMA.4-CHAIN C REGION C-TERMINAL FRAGMENT), DISULFIDE WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN CLONE 4B6 .KAPPA.-CHAIN V-J REGION) FUSION PROTEIN WITH LINKER PEPTIDE (GGGSGGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS CLONE MG13.78 HEAVY CHAIN V-D-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGCGGG) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC K-COIL), DIMER

LORIGERLIMAB [USAN]

Lorigerlimab [WHO-DD]

lorigerlimab [INN]